EDAP and Epitarget team up on cancer drugs

16 Apr 2008 | News

French ultrasound equipment specialist EDAP TMS SA, of Lyon, agreed a research cooperation with Epitarget AS, of Oslo, to work at improving delivery of cancer drugs using a combination of ultrasound-sensitive liposomes and therapeutic ultrasound.

The collaboration will also involve the INSERM Unit 556 in Lyon, which specialises in therapeutic applications of ultrasound.

The project, ‘Novel Sonosensitive Liposomes and Systems for Targeted Ultrasound Mediated Drug Delivery,’  has been awarded a public grant from the French Norwegian Foundation, the French Ministry of Research and the French Innovation Society, and has the backing of the EUREKA industrial research programme.

Emmanuel Blanc, EDAP’s R&D Director, said, “We are confident that the use of our patented technology can be used to precisely deliver drugs encapsulated within liposomes to deep-seated tumors while facilitating drug absorption by cancer cells.”

Marc Oczachowski, EDAP's Chief Executive Officer, said that EDAP is recognised as leader in the treatment of localised prostate cancer using ultrasound. “We are excited to be expanding our expertise across other pathologies.”

Never miss an update from Science|Business:   Newsletter sign-up